Since the market sees this event as broadly positive for pharmaceutical companies, ABBV's stock has risen significantly.

After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.

Eli Lilly’s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside.

Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand ...

Key Takeaways The S&P 500, Dow, and Nasdaq were little changed Wednesday afternoon as a federal government shutdown took ...

Over the past 10 years, the stock has attracted buying interest at this level 5 times and subsequently achieved an average ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $934.09, a high estimate of $1135.00, ...

Shares of Eli Lilly LLY have surged 16% in the past week, driven primarily by positive investor expectations around the ...

Eli Lilly’s valuation has compressed significantly from last year’s highs, despite improving fundamentals. See why I rate LLY ...

Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.

Prediction markets are an increasingly big business, and Wall Street wants in on the action. Intercontinental Exchange, the ...

Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.